Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Bevacizumab vs Triamcinolone for Keloids
NCT07014280Phase 4Active, not recruiting
- Sponsor
- Kasr Al Ainy Hospital
- Start
- Sep 2023
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of bevacizumab in keloid, sponsored by Kasr Al Ainy Hospital. Started Sep 2023; status: active, not recruiting.
02
Drugs
bevacizumab
03
Conditions
keloid
Beyond the preview
Go deeper on NCT07014280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07014280.